GO
Loading...

Bristol-Myers Squibb Co

More

  • Nikkei edges up, BOJ's ETF buying helps sentiment Wednesday, 4 Mar 2015 | 9:28 PM ET

    *Rakuten falls after Goldman cuts rating. TOKYO, March 5- Japan's Nikkei share average edged up on Thursday after the central bank bought more exchange-traded funds, but gains were limited by investor caution ahead of U.S. jobs data on Friday. Ono Pharmaceutical Co, which co-develops cancer treatment drug Opdivo with Bristol Myers Squibb, jumped 8 percent after...

  • Final Glance: Pharmaceuticals companies Wednesday, 4 Mar 2015 | 6:17 PM ET

    Baxter International Inc. fell$. 17 or. 2 percent, to $69.25. Bristol-Myers Squibb Co. rose $3.75 or 6.1 percent, to $65.67. Eli Lilly& Co. rose$. 28 or. 4 percent, to $70.65.

  • *Markit, ISM services show modest growth. *Healthcare stocks rise after Supreme Court oral argument. The market had a terrific February, "said David Katz, chief investment officer at Matrix Asset Advisors, in New York.

  • FDA approves Bristol-Myers drug for lung cancer Wednesday, 4 Mar 2015 | 2:22 PM ET

    WASHINGTON— The Food and Drug Administration on Wednesday expanded approval of an innovative Bristol-Myers Squibb drug to treat the most common form of lung cancer. The FDA first approved Bristol's drug in December for melanoma, the deadliest form of skin cancer. Evercore ISI analyst Mark Schoenebaum said in an investment note that Opdivo could garner sales...

  • Midday Glance: Pharmaceuticals companies Wednesday, 4 Mar 2015 | 1:16 PM ET

    Baxter International Inc. rose$. 11 or. 2 percent, to $69.53. Bristol-Myers Squibb Co. rose$. 86 or 1.4 percent, to $62.78. Eli Lilly& Co. rose$. 16 or. 2 percent, to $70.53.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • Early Glance: Pharmaceuticals companies Wednesday, 4 Mar 2015 | 10:36 AM ET

    Baxter International Inc. fell$. 28 or. 4 percent, to $69.14. Bristol-Myers Squibb Co. fell$. 40 or. 6 percent, to $61.52. Eli Lilly& Co. fell$. 43 or. 6 percent, to $69.94.

  • COPENHAGEN, March 4- Bavarian Nordic has struck a prostate cancer drug deal with Bristol-Myers Squibb that could be worth $1 billion should its trials, part of a new field in cancer treatment, be successful. The jump added over $260 million to its market value of $880 million. In that trial, patients were treated with Prostvac in addition to escalating doses of...

  • COPENHAGEN, March 4- Shares in Bavarian Nordic leapt as much as 39 percent on Wednesday after the Danish biotech company announced a prostate cancer drug deal with Bristol-Myers Squibb that could be worth at least $1 billion. Under the deal, Bavarian Nordic could receive up to $975 million, including $60 million upfront, if it passes trials and sales milestones,...

  • Final Glance: Pharmaceuticals companies Tuesday, 3 Mar 2015 | 6:05 PM ET

    Baxter International Inc. fell$. 54 or. 8 percent, to $69.42. Bristol-Myers Squibb Co. fell$. 38 or. 6 percent, to $61.92. Eli Lilly& Co. fell$. 75 or 1.1 percent, to $70.37.

  • Final Glance: Pharmaceuticals companies Monday, 2 Mar 2015 | 6:08 PM ET

    Baxter International Inc. rose$. 81 or 1.2 percent, to $69.96. Bristol-Myers Squibb Co. rose $1.38 or 2.3 percent, to $62.30. Eli Lilly& Co. rose$. 95 or 1.4 percent, to $71.12.

  • Early Glance: Pharmaceuticals companies Monday, 2 Mar 2015 | 11:16 AM ET

    Baxter International Inc. rose$. 34 or. 5 percent, to $69.49. Bristol-Myers Squibb Co. rose$. 81 or 1.3 percent, to $61.73. Eli Lilly& Co. rose$. 78 or 1.1 percent, to $70.95.

  • Final Glance: Pharmaceuticals companies Friday, 27 Feb 2015 | 6:02 PM ET

    Baxter International Inc. rose$. 48 or. 7 percent, to $69.15. Bristol-Myers Squibb Co. fell$. 54 or. 9 percent, to $60.92. Eli Lilly& Co. rose$. 14 or. 2 percent, to $70.17.

  • Midday Glance: Pharmaceuticals companies Friday, 27 Feb 2015 | 1:26 PM ET

    Baxter International Inc. rose$. 69 or 1.0 percent, to $69.36. Bristol-Myers Squibb Co. fell$. 26 or. 4 percent, to $61.20. Eli Lilly& Co. rose$. 32 or. 5 percent, to $70.35.

  • Early Glance: Pharmaceuticals companies Friday, 27 Feb 2015 | 11:10 AM ET

    Baxter International Inc. rose$. 33 or. 5 percent, to $69.00. Eli Lilly& Co. fell$. 03 or percent, to $70.00. Hospira fell$. 03 or percent, to $87.51.

  • Final Glance: Pharmaceuticals companies Thursday, 26 Feb 2015 | 6:02 PM ET

    Baxter International Inc. fell$. 19 or. 3 percent, to $68.67. Bristol-Myers Squibb Co. rose$. 24 or. 4 percent, to $61.46. Eli Lilly& Co. fell$. 33 or. 5 percent, to $70.03.

  • Midday Glance: Pharmaceuticals companies Thursday, 26 Feb 2015 | 1:19 PM ET

    Baxter International Inc. fell$. 03 or percent, to $68.83. Bristol-Myers Squibb Co. rose$. 27 or. 4 percent, to $61.49. Eli Lilly& Co. fell$. 57 or. 8 percent, to $69.79.

  • Early Glance: Pharmaceuticals companies Thursday, 26 Feb 2015 | 10:35 AM ET

    Baxter International Inc. fell$. 11 or. 2 percent, to $68.75. Bristol-Myers Squibb Co. fell$. 42 or. 7 percent, to $60.80. Eli Lilly& Co. fell$. 70 or 1.0 percent, to $69.66.

  • Midday Glance: Pharmaceuticals companies Wednesday, 25 Feb 2015 | 1:18 PM ET

    Baxter International Inc. fell$. 16 or. 2 percent, to $68.90. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $61.30. Eli Lilly& Co. fell$. 24 or. 3 percent, to $70.66.

  • Early Glance: Pharmaceuticals companies Wednesday, 25 Feb 2015 | 11:23 AM ET

    Baxter International Inc. fell$. 09 or. 1 percent, to $68.97. Bristol-Myers Squibb Co. fell$. 40 or. 7 percent, to $61.05. Johnson& Johnson fell$. 40 or. 4 percent, to $100.30.